Full Breakdown
ADHD Linked to Substantially Higher Mortality; Medication May Cut Risk by One-Quarter
By Drooid · · How we work
Core Findings of the Systematic Review
A systematic review and meta-analysis published in *JAMA Network Open* examined 19 observational cohort studies that together tracked nearly 16 million participants across three continents. Researchers at University College London and the University of Liverpool found that individuals diagnosed with attention-deficit/hyperactivity disorder (ADHD) experience about a 70 % higher risk of death from any cause compared with people without the diagnosis. The excess risk is spread across several categories:
- Suicide: roughly 90 % higher risk.
- Injury (intentional or accidental): 55 % higher risk.
- Natural-cause mortality (e.g., cardiovascular disease, diabetes, cancer): 27 % higher risk.
Potential Protective Role of ADHD Medication
Among the 19 studies, only three compared mortality outcomes for people with ADHD who were prescribed medication versus those who were not. In those analyses, medicated individuals showed a 25 % lower overall mortality risk. The authors note that this signal is based on a small subset of the data and that the observational nature of the studies precludes causal inference.
Official Statements & Responses
- Professor Joshua Stott, senior author at University College London, emphasized that the heightened mortality is “broad and wide-ranging” and includes suicide, injury, and natural-cause deaths.
Data & Statistics
| Mortality Category | Relative Increase vs. Non-ADHD |
|---|---|
| All-cause death | +70 % (? 1.7 ×) |
| Suicide | +90 % (? 1.9 ×) |
| Injury (intentional or accidental) | +55 % (? 1.55 ×) |
| Natural causes | +27 % (? 1.27 ×) |
| Medication-associated risk reduction | –25 % (relative) |
The review noted substantial heterogeneity across studies, with variations in diagnostic criteria, healthcare access, and follow-up periods (some exceeding two decades). Socio-economic status and co-occurring mental-health conditions were not uniformly controlled.
Conflicting Reports & Gaps
- The magnitude of the overall mortality increase varies slightly among sources, but all report a substantial elevation.
- The medication-related risk reduction is derived from only three studies (Taiwan, Canada, Sweden), and participants who receive medication may differ in unmeasured ways (e.g., health-service engagement, symptom severity).
- No randomized controlled trials were identified; all evidence is observational, limiting causal inference.
- Some individual studies produced confidence intervals that included no added risk, highlighting the need for more uniform, prospective research.
Why the Findings Matter
The review positions ADHD as a long-term public-health concern, extending the focus beyond childhood behavioral symptoms to adult mortality risk. The authors stress comprehensive, equitable care—including accurate diagnosis, sustained treatment, and support for health-service navigation—to mitigate the broad health inequalities identified.